MedImmune

MedImmune

MedImmune is the global biologics research and development arm of AstraZeneca and is pioneering innovative research and exploring novel pathways across key therapeutic areas, including oncology; respiratory; and cardiovascular and metabolic disease.

Address: Milstein Building, Granta Park , Cambridge
Postcode: CB21 6GH
Country: United Kingdom
Website: http://www.medimmune.com
Membership type:Founder Member

MedImmune is the global biologics research and development arm of AstraZeneca with candidate biologics and vaccines that currently compromise approximately 50 per cent of AstraZeneca’s overall R&D pipeline.   It has one of the most robust and promising pipelines in the biologics industry, with more than 120 biologics in research and development and over 40 projects in clinical stage development.

MedImmune is pioneering innovative research and exploring novel pathways across key therapeutic areas, including oncology; respiratory; and cardiovascular and metabolic disease. In addition, the company is opportunistic in infectious disease and vaccines. Approximately 2,200 full-time employees are in the US and UK. MedImmune is headquartered in Gaithersburg, MD – one of AstraZeneca’s three global R&D centres, along with Cambridge, UK and MoIndal, Sweden

MedImmune’s Cambridge team is focused on the research and early development of our biologics portfolio. MedImmune has built on the local legacy of Cambridge Antibody Technology (CAT) – acquired by AstraZeneca and integrated with MedImmune in 2007 – where three marketed products (Humira, Benlysta and raxibacumab) were invented.  With over 600 employees, MedImmune Cambridge has strong collaborative links with numerous academics, researchers, foundations and neighbouring companies in the largest biotech cluster in Europe and has an active outreach programme within the local community.

1 Humira is a registered trademark of AbbVie Inc.
2 Benlysta is a registered trademark of GlaxoSmithKline

MedImmune is the global biologics R&D arm of AstraZeneca

MedImmune is the global biologics research and development arm of AstraZeneca, focused on pioneering research and exploring novel mechanisms and pathways across key therapeutic areas.

MedImmune and Ventana Medical Systems, Inc. collaborate for immunotherapy clinical trials

MedImmune, the global biologics research and development arm of AstraZeneca, and Ventana Medical Systems, Inc., a member of the Roche Group, announced they are jointly developing a PD-L1 (SP263) immunohistochemistry assay to enroll patients in clinical trials for MedImmune’s MEDI4736 anti-PD-L1 therapy for non-small cell lung carcinoma.

5 June 2014Read in full

AstraZeneca’s MedImmune presents encouraging immunotherapy data at ASCO 2014

Data support rapid progression to Phase III development for MEDI4736 (PD-L1); highlight progress of company’s oncology portfolio.

4 June 2014Read in full

MedImmune and Incyte announce collaboration on immuno-oncology combination clinical trial

AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a clinical study collaboration with biopharmaceutical company Incyte Corporation.

14 May 2014Read in full

MedImmune expands University System of Maryland research collaboration

MedImmune, the global biologics research and development arm of AstraZeneca, and the University System of Maryland announced that the initial research collaboration between MedImmune and the University of Maryland, Baltimore (UMB) has been expanded.

30 April 2014Read in full

MedImmune and MD Anderson join forces to advance cancer immunotherapy

MedImmune, AstraZeneca’s global biologics research and development arm, announced it has entered into a three-year translational and clinical research collaboration with The University of Texas MD Anderson Cancer Center to study therapies that unleash patients’ immune systems to attack their cancers through MD Anderson’s Moon Shots Program.

14 March 2014Read in full

Credit: Kevin Brindle

MedImmune and University of Cambridge announce oncology research collaboration

MedImmune, the global biologics research and development arm of AstraZeneca, and the University of Cambridge today announced they have entered into a three-year oncology research collaboration. This partnership aims to advance cancer research by using imaging technologies to measure key biologic changes within growing tumours.

12 March 2014Read in full

MedImmune and Immunocore enter immunotherapy agreement to develop novel cancer therapies

AstraZeneca has announced that MedImmune, its global biologics research and development arm, has entered into an oncology research collaboration and licensing agreement with Immunocore Limited, a privately-held, UK-based biotechnology company.

9 January 2014Read in full

Carla Pilsworth (left) with Jane Osbourn (right) and colleagues

MedImmune celebrates 25 years of biotech innovation

MedImmune, the global biologics research and development arm of AstraZeneca, is celebrating its 25th anniversary with a donation to Macmillan Cancer Support.

26 November 2013Read in full

MedImmune supports Institute of Metabolic Science seminar series

MedImmune, the global biologics research and development arm of AstraZeneca, is pleased to announce that it is supporting the Institute of Metabolic Science’s 2013-14 external research seminar series in Cambridge through the provision of an educational grant. The seminars are widely attended and focus on a wide range of topics within the field of metabolic disease research.

19 November 2013Read in full

Dr Monika Papworth receives her award

MedImmune scientist wins Royal Society of Chemistry Education Award

MedImmune, the global biologics research and development arm of AstraZeneca, is pleased to congratulate Dr Monika Papworth, a scientist based at the company’s Cambridge site, on receiving the Royal Society of Chemistry’s Inspiration and Industry Award 2013 in recognition of her “creative ideas to build scientific understanding of chemistry and biology in schools and science festivals.”

12 November 2013Read in full

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6